H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on WHWK stock, giving a Hold rating on October 24.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Hold rating due to a combination of factors surrounding Whitehawk Therapeutics. The company’s recent financial results showed a higher net loss per share than previously estimated, indicating some financial challenges. Despite having a substantial cash reserve that could support operations into 2028, the company faces uncertainties with its upcoming clinical trials and drug development.
Additionally, while there are several anticipated catalysts, such as IND submissions for new drug candidates, these are still in early stages and not yet included in the company’s valuation due to the lack of clinical efficacy data. Furthermore, potential risks such as disappointing market uptake of their existing product, FYARRO, and challenges in developing it for other cancer indications contribute to the cautious outlook. As a result, Burns maintains a Neutral stance, opting to reassess the situation as the company’s lead candidates progress further in development.
In another report released on October 24, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $2.50 price target.